報(bào)告題目：Selective survivin inhibitors for cancer therapy
報(bào) 告 人 ：Professor Wei Li
報(bào)告時(shí)間：2018年6月15日下午3:00
報(bào)告地點(diǎn)：化學(xué)樓二樓一號(hào)會(huì)議室
邀 請(qǐng) 人 ：尹國(guó)川教授
報(bào)告人簡(jiǎn)介：
Prof. Li received his BS degree from USTC and his PhD degree in Chemistry in 1999 from Columbia University. He is a Professor of Medicinal Chemistry, the Director of the University of Tennessee College of Pharmacy (UTCoP) Drug Discovery Center, and the Faculty Director of Shared Analytical Instrument Facility. He serves as an Editorial Board Member for Current Medicinal Chemistry and Acta Pharmaceutica Sinica B. His area of research is small molecule drug discovery and his lab is currently supported by ~$4 million dollars of research funding. He has published over 140 papers, is an inventor of five issued US patents and additional large numbers of patents from other countries, and is a frequent grant reviewer for the US NIH, NSF, other US Government and State Agencies, and cancer related funding agencies from other countries.
報(bào)告摘要：
Selective targeting the cancer cell apoptosis pathway is an attractive strategy for developing new anticancer agents. The antiapoptotic protein, survivin, is highly expressed in cancer cells and fetus tissues, but its expression is very low in fully differentiated adult cells. Thus small molecules selectively target survivin could serve as a potential anticancer drug. His lab has recently developed a small molecule survivin inhibitor. He will describe this project in his talk.
